中国工程院院士、广州国家实验室主任钟南山，中国医院协会常务副会长毛群安，广东省政务服务和数 据管理局局长王天广，广州市政务服务和数据管理局局长黄津，广州市卫生健康委副主任李铁钢，广州 医科大学副校长付晓东，中国信息产业商会工业互联网分会理事长、广东省数据要素产业协会负责人朱 立锋、金域医学董事长兼首席执行官梁耀铭等出席大会。大会吸引了来自海内外超过400位医疗机构、 IVD企业、药企、大数据及人工智能等领域专家参与，近70名专家学者与企业领军人物登台分享。 王天广表示，健康医疗数据是国家重要基础性战略资源，也是医学人工智能发展的关键基础资源。他发 出三点倡议：一是打造全国领先的高质量数据集，全面赋能诊疗、公卫、新药研发等环节；二是加快建 设医疗数据基础设施，依托可信数据空间链接全流程数据资源，探索医疗健康领域数字经济发展新路 径；三是构建粤港澳大湾区"AI+医疗"创新圈，通过优化数据资产管理、探索数据质量评价标准、推动 数据合规流通，全面支撑人工智能在医疗领域的应用。"我们诚挚期待更多高水平的医疗机构、科研院 所和科技企业，能够参与到大湾区医学人工智能的创新实践中来，与我们携手并进，全力打造全球生物 医药创新 ...

Core Insights - The first Greater Bay Area Medical Artificial Intelligence Conference was held on December 7, aiming to promote the integration of medical AI and big data, establishing a smart healthcare ecosystem with international influence [1] - The conference highlighted the urgent need for collaboration among institutions to advance medical AI, emphasizing that it is not a choice but a necessity for the future of healthcare [2] Group 1: Conference Overview - The conference was organized by various associations and institutions, attracting over 400 experts from medical, IVD, pharmaceutical, big data, and AI fields [1] - Key figures in attendance included prominent medical professionals and government officials, indicating the high-level support for the initiative [1] Group 2: Key Statements - Academician Zhong Nanshan emphasized that medical AI is essential for the future, and collaboration among institutions is crucial for its development [2] - He also noted that while AI can enhance efficiency, it cannot replace the human aspects of healthcare, such as understanding patients' emotional needs [3] Group 3: Data and Infrastructure Initiatives - The establishment of a national medical testing data circulation platform was announced, aimed at enhancing the quality of healthcare data and supporting AI applications in medicine [3][4] - The platform is expected to expand its cooperative network and develop new data products, positioning itself as a national open and win-win medical testing data circulation platform [4] Group 4: Company Developments - KingMed Medical has showcased its achievements in medical AI and data science, presenting a product blueprint that addresses key clinical challenges [6] - The company has developed several AI products and models, significantly improving diagnostic efficiency and providing support to a large number of healthcare professionals and users [6] Group 5: Collaborative Efforts - KingMed Medical has signed cooperation agreements with 18 institutions to foster innovation in specialized disease models, data circulation, and health management [7] - The company aims to build a smart healthcare ecosystem by leveraging data and clinical expertise, ensuring safe data circulation and maximizing AI's value in clinical settings [7]

Core Insights - The first Greater Bay Area Medical Artificial Intelligence Ecosystem Conference was held in Guangzhou, marking a significant step in the rapid development of AI applications in medical diagnostics in China [1][2] - The conference attracted over 400 experts and featured discussions on the necessity of collaboration among institutions to advance medical AI [2][4] Group 1: Medical AI Development - The development of medical AI is deemed an inevitable choice, with a strong emphasis on the need for collaboration among various institutions, particularly in integrating industry, academia, and research [2][4] - AI is expected to enhance the clinical capabilities of grassroots doctors by leveraging decades of clinical experience, although it cannot replace the human aspects of medical care [2][4] Group 2: Data Space and Collaboration - The "Trusted Medical Data Space" was officially launched by KingMed Medical, which is the only medical institution selected as a pilot for the national trusted data space initiative [3][4] - KingMed Medical has signed cooperation agreements with 18 institutions to foster collaboration in specialized disease model development, AI applications, and data flow [4][5] Group 3: KingMed Medical's Innovations - KingMed Medical has developed a comprehensive product blueprint that includes intelligent product services, specialized disease model services, user health services, and the trusted medical data space [4] - Since implementing the "Medical Testing 4.0" strategy in 2020, KingMed has created the industry's first large model "Yujian Yiyan" and the intelligent agent "Xiaoyue Yi," interpreting nearly 8 million reports [4]

Core Points - The sixth National Excellent Builders of Socialism with Chinese Characteristics Award Ceremony was held on July 29, recognizing 100 individuals, including six entrepreneurs from Guangdong [1] Group 1: Recognized Entrepreneurs - Liang Yaoming, CEO of Guangzhou Kingmed Diagnostics Group Co., Ltd., founded the company in the 1990s, leading it to become the largest third-party medical testing institution in China with the most comprehensive service network and international recognition [1] - Zhang Chunhua, Chairman of Shenzhen Langhua Investment Holdings Co., Ltd., has focused on cost reduction and efficiency improvement in the manufacturing industry for 20 years, while also engaging in public welfare and policy advocacy [2] - Wu Fengli founded Guangdong Tosstar Technology Co., Ltd. in 2007, which became the first robotics company from Guangdong to list on the Growth Enterprise Market, emphasizing technological innovation and industry advancement [2] - Zeng Qingming established Guangdong Suocheng Technology Co., Ltd. in 2013, achieving a compound annual growth rate of over 30% and breaking foreign monopolies through innovation [3] - Tang Yu returned to his hometown in 2017 to promote rural revitalization through digital technology and e-commerce, creating a model centered around the "Dogzi Bean" industry chain [3] - Gao Qing, as a technical leader, drives innovation in private enterprises and actively participates in community initiatives in Shenzhen [3]

Core Viewpoint - The inclusion of Guangzhou Kingmed Diagnostics Group Co., Ltd. in the first batch of trusted data space innovation development pilot projects signifies national recognition of its practices in medical data security and application, addressing the challenges of data sharing in the healthcare industry [1][2]. Group 1: Company Overview - Kingmed Diagnostics has over 30 years of experience in the medical testing industry, possessing a core asset of more than 3 billion medical testing data and a service network covering over 90% of the Chinese population [2]. - The company serves more than 23,000 medical institutions, positioning itself as a pioneer in the marketization of medical data elements [2]. Group 2: Industry Impact - The pilot project aims to break the long-standing data isolation issues in the medical industry, enhancing the value of data as a production factor and promoting compliant circulation of medical data [2]. - The trusted data space is viewed as a "data safe house," allowing different data providers to share data securely, which is crucial for the healthcare sector [1][2]. Group 3: Future Strategy - Kingmed Diagnostics plans to leverage the trusted data space as a key infrastructure for its "data + AI" strategy, aiming to create a second growth curve driven by data elements [2]. - The company intends to enhance the platform attributes and public service functions of the data space over the next five years, attracting more hospitals, doctors, and individuals to participate [2].

Summary of Jin Domain Medical Conference Call Company Overview - **Company**: Jin Domain Medical - **Industry**: Third-party medical testing Key Financial Performance - **2024 Revenue**: Decreased by 15.81% to 7.19 billion CNY [2][3] - **2024 Net Profit**: Reported at -0.38 billion CNY, a decline of 159.26% [3] - **2024 Operating Cash Flow**: Decreased by 26.36% to 906 million CNY [3] - **2025 Q1 Revenue**: Decreased by 20.35% to 1.467 billion CNY [4] - **2025 Q1 Net Profit**: Reported at -0.028 billion CNY, a decline of 49.09% [4] - **2025 Q1 Operating Cash Flow**: Increased by 139% to 55 million CNY [4] Key Challenges - **Market Demand**: Slowed down, impacting revenue [2][3] - **Cost Increases**: Rising fixed costs and extended accounts receivable cycles led to significant credit impairment losses of 619.48 million CNY [3] - **Investment Shortfalls**: Investments did not meet expectations, contributing to losses [2][3] Strategic Initiatives - **Customer-Centric Approach**: Focus on building a differentiated service system and launching high-sensitivity testing products [2][5] - **Cost Reduction Measures**: Implementing capacity layout and reagent procurement strategies to enhance efficiency [2][5] - **Digital Transformation**: Accelerating digital initiatives, including the launch of the "Encounter Medical Research Model" [2][5] Future Outlook - **Industry Confidence**: Optimism about the long-term demand driven by an aging population and the gradual recovery from the pandemic [3][6][7] - **Cost Advantages**: Scale production aligns with medical insurance cost control trends [7] - **Long-term Development Philosophy**: Commitment to sustainable growth rather than short-term profits [7] 2025 Strategic Focus - **Adaptation to External Changes**: Emphasizing a shift in mindset to address industry competition and cost pressures [8] - **Enhancing Professional Capabilities**: Improving service levels while reducing operational costs [8] - **Digital Business System**: Further exploration of large models in service enhancement and operational management [8] Industry Perspective - **Bright Future for Third-party Medical Testing**: The industry is expected to benefit from ongoing healthcare demands and policy support [9][10] - **Efficiency Requirements**: The trend towards cost control in medical insurance necessitates higher industry efficiency, particularly for leading enterprises [10]

Core Insights - The company, Kingmed Medical, released its 2024 Sustainable Development Report, marking its first comprehensive disclosure based on the four-element framework for sustainable development reports for listed companies [1] - Kingmed Medical integrates sustainable development goals with its operations, focusing on medical testing technology innovation and digital tools to provide precise medical testing services throughout the lifecycle [1] Group 1: Sustainable Development and Innovation - Kingmed Medical has launched the intelligent application "Xiaoyu Medical," which has served over 13,000 grassroots medical institutions, enhancing the quality of medical services and addressing resource shortages in these areas [2] - The company has developed the first large model in the medical testing industry, "Yujian Yiyan," and the intelligent application "Xiaoyu Medical," which offers project consultation, report interpretation, knowledge Q&A, and medication guidance [2] - The company has provided medical testing cooperation and smart medical testing services to 128 tightly-knit county medical communities [3] Group 2: Affordable Healthcare Initiatives - Kingmed Medical's affordable product series has served over 2 million people, aiming to lower the barriers to medical testing and make high-end medical technology accessible to a broader population [4] - The "Hui Min 3000" tumor gene testing system covers 18 common solid tumors and is priced under 3,000 yuan, helping 30,000 patients achieve precise diagnoses [4] Group 3: Community Support and Rural Revitalization - Kingmed Medical collaborates with the Guangzhou Kingmed Charity Foundation to engage in health assistance, industry support, education, and charity in 140 poverty-stricken counties, including 31 key rural revitalization counties [5] - The company has established 182 medical laboratories in 15 provinces and regions, enhancing medical testing and pathological diagnosis services in these areas [5] - Kingmed Medical has conducted over 220 public welfare activities, covering various diseases and reaching 29 provinces and regions across the country [6]

Group 1 - The core viewpoint of the articles is that Kingmed Medical has launched a new integrated solution for county medical communities, focusing on digital empowerment, professional services, and resource sharing to enhance the quality of grassroots medical care and promote hierarchical diagnosis and treatment [2][6][9] - The new solution incorporates a "digital intelligence" element, utilizing Kingmed's self-developed domain-specific AI model and the intelligent application "Xiaoyuyi" to improve digital governance capabilities and facilitate information sharing within the medical community [2][8] - The construction of county medical communities is progressing, with a goal of having over 90% of counties establish tight-knit medical communities by the end of 2025, but challenges in information technology and resource allocation remain [4][6] Group 2 - Kingmed Medical's integrated solution aims to address the bottlenecks in county medical community construction by providing a comprehensive service that includes laboratory management, quality control, and professional talent training [6][7] - The solution features a dual-driven model of "software + intelligent agent," which customizes information platform services for different county medical communities, integrating various systems to enhance clinical decision-making [8][9] - Kingmed Medical has established a nationwide service network and has collaborated with over 700 medical institutions, serving 128 tight-knit county medical communities to improve grassroots diagnostic capabilities [7][9]

Core Insights - The company reported a total revenue of 7.19 billion yuan for 2024, with a net profit attributable to shareholders of -0.38 billion yuan due to credit impairment losses of 0.62 billion yuan, but showed strong cash flow performance with operating net cash flow reaching 0.906 billion yuan [2] - In Q1 2025, the operating net cash flow turned positive at 0.0545 billion yuan, compared to -0.138 billion yuan in Q1 2024 [2] Group 1: Financial Performance - The total revenue for 2024 was 71.90 billion yuan, with a net profit of -3.81 billion yuan due to credit impairment losses of 6.19 billion yuan [2] - Operating net cash flow for 2024 was 9.06 billion yuan, showing a quarterly increase [2] - In Q1 2025, the operating net cash flow improved to 54.5 million yuan, a significant recovery from the previous year's loss [2] Group 2: Market Position and Growth - The specimen testing volume increased by 2.94% year-on-year, with a stable market share despite industry adjustments [3] - Revenue from tertiary hospitals accounted for 50.88% of total revenue, an increase of 7.75 percentage points year-on-year [3] - The company has established partnerships with 34 new top-tier hospitals and has built over 90 high-end precision medicine centers nationwide [3] Group 3: Digital Transformation and AI Integration - The company has over 570,000 registered users on its service platform, with the "Xiao Yu Yi" application seeing rapid growth to 89,000 registered doctors [4] - AI applications have improved diagnostic efficiency by 50% to 90% across various areas, with automated report generation increasing efficiency by 70% [4] - The company has completed the first batch of data asset registration, valued at 7.22 million yuan, marking a significant step in its digital transformation [5] Group 4: Data Utilization and Research Contributions - The company possesses the largest medical data volume in the country at 23.6 PB, growing at a rate of 1 PB per year [5] - Five data products have been launched on the Guangzhou Data Exchange, with initial transactions completed [5] - Collaborative research has led to three publications in top international journals, contributing to public health decision-making and disease prevention [5]

Group 1 - The company reported a revenue of RMB 928 million for the year ending December 31, 2024, with a gross profit of RMB 440 million and a net loss of RMB 60.68 million, resulting in a loss per share of 5.77 cents [1] - The decline in gross profit was attributed to a revenue decrease of RMB 39.7 million and increased fixed asset investments, including the establishment of new laboratories in Shanghai and Guangzhou [1] - Despite the decline in gross profit, the gross margin improved compared to 2023 due to product structure enhancement, cost control, and efficiency improvements [1] Group 2 - In 2024, China's regulatory scrutiny of the healthcare industry intensified, leading to a critical period of adjustment and standardization for the third-party medical testing industry, posing challenges to operational strategies, business models, and compliance management [2] - The demand for precision medicine and specialized testing is increasing due to economic development and heightened public health awareness, providing opportunities for companies in the sector [2] - The company aims to leverage its deep expertise in specialized testing to expand its focus areas through multiple technology platforms and testing projects, while also pursuing strategic acquisitions for business expansion and resource optimization [2]